PLK1 and cancer: Targeting Plk1 by siRNA or small molecule inhibitors effectively reduces cell proliferation, causes cell cycle arrest, induces apoptosis, inhibits cell invasion, and increases the sensitivity to chemotherapeutic agents through β-catenin/c-Myc, AKT/mTOR, and ERK Pathways in multiple pre-clinical models of cancer (Matthess et al., 2014; Song et al., 2018; Fu and Wen, 2017; Wang et al., 2023; Choi et al., 2023).